Recommendations of Gentamicin Dose Based on Different Pharmacokinetic/Pharmacodynamic Targets for Intensive Care Adult Patients: A Redefining Approach

References

• Gentamicin Injection USP. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/062366s033lbl.pdf. Accessed May 15, 2022.
   Google Scholar
• Dhingra S, Rahman NAA, Peile E, et al. Microbial resistance movements: an overview of global public health threats posed by antimicrobial resistance, and how best to counter. Front Public Health. 2020;8:535668. doi:10.3389/fpubh.2020.535668
   PubMed Web of Science ®Google Scholar
• Craig WA. Optimizing aminoglycoside use. Crit Care Clin. 2011;27(1):107–121. doi:10.1016/j.ccc.2010.11.006
   PubMed Web of Science ®Google Scholar
• Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient - concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014;77:3–11. doi:10.1016/j.addr.2014.07.006
   PubMed Web of Science ®Google Scholar
• Duong A, Simard C, Wang YL, Williamson D, Marsot A. Aminoglycosides in the Intensive Care Unit: what is new in population PK modeling? Antibiotics. 2021;10(5):507. doi:10.3390/antibiotics10050507
   Google Scholar
• Bland CM, Pai MP, Lodise TP. Reappraisal of contemporary pharmacokinetic and pharmacodynamic principles for informing aminoglycoside dosing. Pharmacother J Hum Pharmacol Drug Ther. 2018;38(12):1229–1238. doi:10.1002/phar.2193
   Google Scholar
• Mouton JW, Jacobs N, Tiddens H, Horrevorts AM. Pharmacodynamics of tobramycin in patients with cystic fibrosis. Diagn Microbiol Infect Dis. 2005;2:123–127. doi:10.1093/jac/dki079
   Google Scholar
• Smith PF, Ballow CH, Booker BM, Forrest A, Schentag JJ. Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. Clin Ther. 2001;23(8):1231–1244. doi:10.1016/s0149-2918(01)80103-x
   PubMed Web of Science ®Google Scholar
• Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med. 2020;46(6):1127–1153. doi:10.1007/s00134-020-06050-1
   PubMed Web of Science ®Google Scholar
• Yamada T, Fujii S, Shigemi A, Takesue Y. A meta-analysis of the target trough concentration of gentamicin and amikacin for reducing the risk of nephrotoxicity. J Infect Chemother. 2021;27(2):256–261. doi:10.1016/j.jiac.2020.09.033
   PubMed Web of Science ®Google Scholar
• Oracle Corporation. Oracle Crystal Ball Classroom Edition [Computer Software]. Version 11.1.2.4. Redwood Shores, CA: Oracle Corporation; 2021.
   Google Scholar
• Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999;43(7):1549–1555. doi:10.1128/AAC.43.7.1549
   PubMed Web of Science ®Google Scholar
• United States Committee on Antimicrobial Susceptibility Testing (USCAST). Aminoglycoside in vitro Susceptibility Test Interpretive Criteria Evaluations, Version 1.3, 2019. USCAST; 2019.
   Google Scholar
• Townsend PL, Fink MP, Stein KL, Murphy SG. Aminoglycoside pharmacokinetics: dosage requirements and nephrotoxicity in trauma patients. Crit Care Med. 1989;17(2):154–157.
   PubMed Web of Science ®Google Scholar
• Sangha KS, Miyagawa CI, Healy DP, Bjornson HS. Pharmacokinetics of once-daily dosing of gentamicin in surgical intensive care unit patients with open fractures. Ann Pharmacother. 1995;29(2):117–119. doi:10.1177/106002809502900201
   PubMed Web of Science ®Google Scholar
• Finnell DL, Davis GA, Cropp CD, Ensom MH. Validation of the Hartford nomogram in trauma surgery patients. Ann Pharmacother. 1998;32(4):417–421. doi:10.1345/aph.17243
   PubMed Web of Science ®Google Scholar
• Niemiec PW Jr, Allo MD, Miller CF. Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive care. Arch Surg. 1987;122(2):207–212. doi:10.1001/archsurg.1987.01400140089012
   PubMed Web of Science ®Google Scholar
• Deeter RG, Krauss EA, Penn F, Nahaczewski AE. Comparison of aminoglycoside clearance and calculated serum creatinine clearances. Ther Drug Monit. 1989;11(2):155–161. doi:10.1097/00007691-198903000-00006
   PubMed Web of Science ®Google Scholar
• Triginer C, Fernández R, Izquierdo I, Rello J, Benito S. Gentamicin pharmacokinetic changes related to mechanical ventilation. DICP. 1989;23(11):923–924. doi:10.1177/106002808902301117
   PubMedGoogle Scholar
• Triginer C, Izquierdo I, Fernández R, et al. Changes in gentamicin pharmacokinetic profiles induced by mechanical ventilation. Eur J Clin Pharmacol. 1991;40(3):297–302. doi:10.1007/BF00315213
   PubMed Web of Science ®Google Scholar
• Oparaoji EC, Siram S, Shoheiber O, Cornwell EE 3rd, Mezghebe HM. Appropriateness of a 4 mg/kg gentamicin or tobramycin loading dose in post-operative septic shock patients. J Clin Pharm Ther. 1998;23(3):185–190. doi:10.1046/j.1365-2710.1998.00126.x
   PubMed Web of Science ®Google Scholar
• Mann HJ, Wittbrodt ET, Baghaie AA, Cerra FB. Effect of pharmacokinetic sampling methods on aminoglycoside dosing in critically ill surgery patients. Pharmacotherapy. 1998;18(2):371–378. doi:10.1002/j.1875-9114.1998.tb03864.x
   PubMed Web of Science ®Google Scholar
• Dorman T, Swoboda S, Zarfeshenfard F, Trentler B, Lipsett PA. Impact of altered aminoglycoside volume of distribution on the adequacy of a three milligram per kilogram loading dose. Critical Care Res Group Surgery. 1998;124(1):73–78.
   Google Scholar
• Tang GJ, Tang JJ, Lin BS, Kong CW, Lee TY. Factors affecting gentamicin pharmacokinetics in septic patients. Acta Anaesthesiol Scand. 1999;43(7):726–730. doi:10.1034/j.1399-6576.1999.430707.x
   PubMed Web of Science ®Google Scholar
• Chelluri L, Jastremski MS. Inadequacy of standard aminoglycoside loading doses in acutely ill patients. Crit Care Med. 1987;15(12):1143–1145. doi:10.1097/00003246-198712000-00015
   PubMed Web of Science ®Google Scholar
• Hassan E, Ober JD. Predicted and measured aminoglycoside pharmacokinetic parameters in critically ill patients. Antimicrob Agents Chemother. 1987;31(11):1855–1858. doi:10.1128/AAC.31.11.1855
   PubMed Web of Science ®Google Scholar
• Chelluri L, Warren J, Jastremski MS. Pharmacokinetics of a 3 mg/kg body weight loading dose of gentamicin or tobramycin in critically ill patients. Chest. 1989;95(6):1295–1297. doi:10.1378/chest.95.6.1295
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Pryka RD, Kuehl PG, Blum RA, Donahue P. Bayesian forecasting of serum gentamicin concentrations in intensive care patients. Clin Pharmacokinet. 1990;18(5):409–418. doi:10.2165/00003088-199018050-00005
   PubMed Web of Science ®Google Scholar
• Zarowitz BJ, Robert S, Mlynarek M, Peterson EL, Horst HM. Determination of gentamicin pharmacokinetics by bioelectrical impedance in critically ill adults. J Clin Pharmacol. 1993;33(6):562–567. doi:10.1002/j.1552-4604.1993.tb04704.x
   PubMed Web of Science ®Google Scholar
• Buijk SE, Mouton JW, Gyssens IC, Verbrugh HA, Bruining HA. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med. 2002;28(7):936–942. doi:10.1007/s00134-002-1313-7
   PubMed Web of Science ®Google Scholar
• Wallace AW, Jones M, Bertino JS Jr. Evaluation of four once-daily aminoglycoside dosing nomograms. Pharmacotherapy. 2002;22(9):1077–1083. doi:10.1592/phco.22.13.1077.33529
   PubMed Web of Science ®Google Scholar
• van Maarseveen E, Man WH, Proost J, Neef C, Touw D. Chronopharmacokinetics of once daily dosed aminoglycosides in hospitalized infectious patients. Int J Clin Pharm. 2015;37(2):342–347. doi:10.1007/s11096-015-0066-7
   PubMed Web of Science ®Google Scholar
• Triginer C, Izquierdo I, Fernández R, et al. Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med. 1990;16(5):303–306. doi:10.1007/BF01706354
   PubMed Web of Science ®Google Scholar
• Beckhouse MJ, Whyte IM, Byth PL, Napier JC, Smith AJ. Altered aminoglycoside pharmacokinetics in the critically ill. Anaesth Intensive Care. 1988;16(4):418–422. doi:10.1177/0310057X8801600406
   PubMed Web of Science ®Google Scholar
• Ambrose PG. Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the society of infectious diseases pharmacists. Pharmacotherapy. 2006;26(1):129–134. doi:10.1592/phco.2006.26.1.129
   PubMed Web of Science ®Google Scholar
• Lodise TP, Lomaestro BM, Drusano GL. Society of Infectious Diseases Pharmacists. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2006;26(9):1320–1332. doi:10.1592/phco.26.9.1320
   PubMed Web of Science ®Google Scholar
• Trang M, Dudley MN, Bhavnani SM. Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selection. Curr Opin Pharmacol. 2017;36:107–113. doi:10.1016/j.coph.2017.09.009
   PubMed Web of Science ®Google Scholar
• Fish DN. Extended-interval dosing of aminoglycoside antibiotics in critically ill patients. J Pharm Pract. 2002;15(2):85–95. doi:10.1106/WKHR-J8JL-FHU5
   Google Scholar
• Andes D, Craig WA. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents. 2002;19(4):261–268. doi:10.1016/s0924-8579(02)00022–5.
   PubMed Web of Science ®Google Scholar
• Kashuba AD, Nafziger AN, Drusano GL, Bertino JS Jr. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother. 1999;43(3):623–629. doi:10.1128/AAC.43.3.623
   PubMed Web of Science ®Google Scholar
• Zelenitsky SA, Harding GK, Sun S, Ubhi K, Ariano RE. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother. 2003;52(4):668–674. doi:10.1093/jac/dkg403
   PubMed Web of Science ®Google Scholar
• Zelenitsky SA, Rubinstein E, Ariano RE, Zhanel GG. Canadian Antimicrobial Resistance Alliance. Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD). J Antimicrob Chemother. 2013;68(1):i67–i72. doi:10.1093/jac/dkt028
   PubMedGoogle Scholar
• Sumi CD, Heffernan AJ, Lipman J, Roberts JA, Sime FB. What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review. Clin Pharmacokinet. 2019;58(11):1407–1443. doi:10.1007/s40262-019-00791-z
   PubMed Web of Science ®Google Scholar
• Gonçalves-Pereira J, Martins A, Póvoa P. Pharmacokinetics of gentamicin in critically ill patients: pilot study evaluating the first dose. Clin Microbiol Infect. 2010;16(8):1258–1263. doi:10.1111/j.1469-0691.2009.03074.x
   PubMed Web of Science ®Google Scholar
• Rea RS, Capitano B, Bies R, Bigos KL, Smith R, Lee H. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit. 2008;30(6):674–681. doi:10.1097/FTD.0b013e31818b6b2f
   PubMed Web of Science ®Google Scholar
• Agence française de sécurité sanitaire des produits de santé. Update on good use of injectable aminoglycosides, gentamycin, tobramycin, netilmycin, amikacin. Pharmacological properties, indications, dosage, and mode of administration, treatment monitoring. Med Mal Infect. 2012;42(7):301–308. doi:10.1016/j.medmal.2011.07.007
   PubMedGoogle Scholar
• Allou N, Allyn J, Levy Y, et al. Assessment of the National French recommendations regarding the dosing regimen of 8mg/kg of gentamicin in patients hospitalised in intensive care units. Anaesth Crit Care Pain Med. 2016;35(5):331–335. doi:10.1016/j.accpm.2015.12.012
   PubMed Web of Science ®Google Scholar
• Roger C, Nucci B, Louart B, et al. Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis. J Antimicrob Chemother. 2016;71(1):208–212. doi:10.1093/jac/dkv291
   PubMed Web of Science ®Google Scholar
• Roger C, Louart B, Elotmani L, et al. An international survey on aminoglycoside practices in critically ill patients: the AMINO III study. Ann Intensive Care. 2021;11(1):49. doi:10.1186/s13613-021-00834-4
   PubMed Web of Science ®Google Scholar
• He S, Cheng Z, Xie F. Pharmacokinetic/pharmacodynamic-guided gentamicin dosing in critically ill patients: a revisit of the Hartford nomogram. Int J Antimicrob Agents. 2022;59(6):106600. doi:10.1016/j.ijantimicag.2022.106600
   PubMed Web of Science ®Google Scholar
• Hoff WS, Bonadies JA, Cachecho R, Dorlac WC. EAST practice management guidelines work group: update to practice management guidelines for prophylactic antibiotic use in open fractures. J Trauma. 2011;70(3):751–754. doi:10.1097/TA.0b013e31820930e5
   PubMedGoogle Scholar
• Llanos-Paez CC, Hennig S, Staatz CE. Population pharmacokinetic modelling, Monte Carlo simulation and semi-mechanistic pharmacodynamic modelling as tools to personalize gentamicin therapy. J Antimicrob Chemother. 2017;72(3):639–667. doi:10.1093/jac/dkw461
   PubMed Web of Science ®Google Scholar
• Drusano GL, Louie A. Optimization of aminoglycoside therapy. Antimicrob Agents Chemother. 2011;55(6):2528–2531. doi:10.1128/AAC.01314-10
   PubMed Web of Science ®Google Scholar
• Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agents Chemother. 1995;39(3):650–655. doi:10.1128/AAC.39.3.650
   PubMed Web of Science ®Google Scholar
• Avent ML, Rogers BA, Cheng AC, Paterson DL. Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity. Intern Med J. 2011;41(6):441–449. doi:10.1111/j.1445-5994.2011.02452.x
   PubMed Web of Science ®Google Scholar
• Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70(3):195–283. doi:10.2146/ajhp120568
   PubMedGoogle Scholar
• Gonzalez-Padilla M, Torre-Cisneros J, Rivera-Espinar F, et al. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2015;70(3):905–913. doi:10.1093/jac/dku432
   PubMed Web of Science ®Google Scholar